Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Vorolanib”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06523049
What this trial is testing

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Who this might be right for
Renal Cell CarcinomaImmunotherapyMolecular Targeted Therapy
Hao Zeng 67
Early research (Phase 1)Ended earlyNCT03511222
What this trial is testing

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Who this might be right for
Solid TumorHepatocellular CarcinomaGastric Cancer+1 more
Washington University School of Medicine 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06577961
What this trial is testing

Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Who this might be right for
Kidney CancerRCCRenal Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 37
Not applicableLooking for participantsNCT06676527
What this trial is testing

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

Who this might be right for
NeoplasmsKidney NeoplasmsUrologic Neoplasms+10 more
Jinling Hospital, China 39
Not applicableNot Yet RecruitingNCT06585878
What this trial is testing

A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaRCCKidney Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT07047001
What this trial is testing

Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma (RCC)Adjuvant
Dong Wen 60
Large-scale testing (Phase 3)Not Yet RecruitingNCT07165418
What this trial is testing

A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

Who this might be right for
Renal Cell Carcinoma (RCC)
Peking University Cancer Hospital & Institute 116
Testing effectiveness (Phase 2)Ended earlyNCT04373369
What this trial is testing

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Extensive-stage Small Cell Lung Cancer
Washington University School of Medicine 11
Testing effectiveness (Phase 2)Looking for participantsNCT07386158
What this trial is testing

Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

Who this might be right for
VorolanibClear Cell Renal Cell Carcinoma (ccRCC)Neoadjuvant Therapy
Sun Yat-sen University 21
Testing effectiveness (Phase 2)Study completedNCT03583086
What this trial is testing

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Who this might be right for
Thymic CarcinomaNon-small Cell Lung CancerRefractory Thoracic Tumors+1 more
Vanderbilt-Ingram Cancer Center 88
Testing effectiveness (Phase 2)Looking for participantsNCT06728852
What this trial is testing

Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study

Who this might be right for
Advanced Non-small Cell Lung Cancer (NSCLC)Recurrent or Metastatic Lung CancerThird-line and Beyond Therapy+1 more
Li-kun Chen 32